top of page
TZ-Ab101
Tumor-Specific Antigen Targeting Strategies for
Solid Tumor Therapy
TZ-Ab101 is designed to eliminate cancer cells presenting the oncogenic KRAS(G12D)
peptide in the context of pMHC class I.
Unlike conventional therapies that lack selectivity for tumor-specific antigens,
our antibody specifically recognizes and binds to KRAS(G12D)–derived pMHC,
enabling precise targeting and killing of cancer cells
Mode of Action & In vitro Efficacy
Crystal Structure
Cytotoxicity Test (CAR-T)
Cell: K562(HLA-C*08:02+/TAP-)
CTL
Non-pulsed
KRAS(G12D)10
Specific lysis (%)
Target only
NTD
18-DE
Specific lysis (%)
20
40
60
80
100
0
Cell: 721.221 (HLA-C*08:02+/TAP-)
NTD
Target only
18-DE
TZ-Ab101
G12D
MHC I
(HLA-C*08:02/β2M)
Non-pulsed
KRAS(G12D)10
SARS
pep
SARS
pep
20
40
60
80
100
0
Progress
Design
Lead
IND Enabling
Remarks
Asset
Hit
Preclinical Study
TZ-Ab101
Awarded a national
research grant
Publication
Discovery of TCR-like antibodies to the KRAS(G12D) neoantigen via in silico-in vitro workflow
Molecular Therapy, in press, 2026
SangPhil Ahn, Tae-Sung Oh, Seonghyuk Suh, Joon-Young Jeon, Sangjoon Lah, Kyeongmin Ryu, Sanghyeon Choi, Hyeonkyeong Kim, Eun Gyo Lee, Hyejin Lee, JooYeon Lee, Yoonji Kim, Sanggil Kim, So Ra Park, Hojin Yoo, So-Young Choi, Joo Eon Lee, Dong-Kyun Kim, Bo Mi Ku, Wooram Jung, Myung-Ju Ahn, Jae U. Jung, Yong-Sung Kim, Byung-Ha Oh*, Bo-Seong Jeong* [*Corresponding authors]
bottom of page